Quality is often described as table stakes in pharmaceutical development. It’s the baseline expectation that’s non-negotiable.
Every organisation must follow good manufacturing practice (GMP) principles, maintain compliance and deliver safe, effective products.
But when something is taken as a given, it’s easy for its strategic importance to be overlooked.
Jennifer Cannon, PhD, President, Commercial BioPharma Solutions, Thermo Fisher Scientific, investigates.
In reality, quality is the most decisive competitive advantage in drug development.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
